Combination of nivolumab + ipilimumab – a new perspective in the treatment of metastatic renal carcinoma

03/2020

MUDr. Jana Katolická, Ph.D.

Onkologicko-chirurgické oddělení FN u svaté Anny, Brno

SUMMARY

For patients with advanced renal cell carcinoma intermediateor poor-risk disease without prior exposure to systemic therapy, the combination of nivolumab plus ipilimumab improves overall survival and progression free survival compared with sunitinib.

Key words

metastatic renal carcinoma, nivolumab + ipilimumab, sunitinib